146 related articles for article (PubMed ID: 24748236)
1. Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin.
Song YD; Zhang KF; Liu D; Guo YQ; Wang DY; Cui MY; Li G; Sun YX; Shen JH; Li XG; Zhang L; Shi FJ
Tumour Biol; 2014 Jul; 35(7):7017-24. PubMed ID: 24748236
[TBL] [Abstract][Full Text] [Related]
2. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A.
Hua G; Liu Y; Li X; Xu P; Luo Y
Oncol Rep; 2014 Jun; 31(6):2727-34. PubMed ID: 24789077
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR.
Zhu Z; Wang CP; Zhang YF; Nie L
Asian Pac J Cancer Prev; 2014; 15(2):917-23. PubMed ID: 24568519
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Huang K; Chen J; Yang MS; Tang YJ; Pan F
Cancer Biomark; 2017; 18(3):231-239. PubMed ID: 28085008
[TBL] [Abstract][Full Text] [Related]
5. Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.
Huang YW; Lin CY; Tsai HC; Fong YC; Han CK; Huang YL; Wu WT; Cheng SP; Chang HC; Liao KW; Wang SW; Tang CH
Aging (Albany NY); 2020 May; 12(10):9475-9488. PubMed ID: 32428872
[TBL] [Abstract][Full Text] [Related]
6. Glutamine metabolism controls amphiregulin-facilitated chemoresistance to cisplatin in human chondrosarcoma.
Wu YY; Law YY; Huang YW; Tran NB; Lin CY; Lai CY; Huang YL; Tsai CH; Ko CY; Chou MC; Huang WC; Cheng FJ; Fong YC; Tang CH
Int J Biol Sci; 2023; 19(16):5174-5186. PubMed ID: 37928274
[TBL] [Abstract][Full Text] [Related]
7. miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism.
Tang XY; Zheng W; Ding M; Guo KJ; Yuan F; Feng H; Deng B; Sun W; Hou Y; Gao L
Drug Des Devel Ther; 2016; 10():571-83. PubMed ID: 26966351
[TBL] [Abstract][Full Text] [Related]
8. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
9. Ajuba overexpression regulates mitochondrial potential and glucose uptake through YAP/Bcl-xL/GLUT1 in human gastric cancer.
Li H; Fu L; Liu B; Lin X; Dong Q; Wang E
Gene; 2019 Apr; 693():16-24. PubMed ID: 30690182
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib causes growth arrest and inhibition of metastasis in human chondrosarcoma cells.
Song J; Zhu J; Zhao Q; Tian B
J BUON; 2015; 20(3):894-901. PubMed ID: 26214645
[TBL] [Abstract][Full Text] [Related]
11. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
14. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.
Kim H; Cho Y; Kim HS; Kang D; Cheon D; Kim YJ; Chang MJ; Lee KM; Chang CB; Kang SB; Kang HG; Kim JH
Nat Commun; 2020 Oct; 11(1):5023. PubMed ID: 33024108
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
[TBL] [Abstract][Full Text] [Related]
16. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
18. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
20. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
